Eosinophilic cardiomyopathy

WikiDoc Resources for Eosinophilic cardiomyopathy
Articles
Most recent articles on Eosinophilic cardiomyopathy Most cited articles on Eosinophilic cardiomyopathy Review articles on Eosinophilic cardiomyopathy Articles on Eosinophilic cardiomyopathy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Eosinophilic cardiomyopathy Images of Eosinophilic cardiomyopathy Photos of Eosinophilic cardiomyopathy Podcasts & MP3s on Eosinophilic cardiomyopathy Videos on Eosinophilic cardiomyopathy
Evidence Based Medicine
Cochrane Collaboration on Eosinophilic cardiomyopathy Bandolier on Eosinophilic cardiomyopathy TRIP on Eosinophilic cardiomyopathy
Clinical Trials
Ongoing Trials on Eosinophilic cardiomyopathy at Clinical Trials.gov Trial results on Eosinophilic cardiomyopathy Clinical Trials on Eosinophilic cardiomyopathy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Eosinophilic cardiomyopathy NICE Guidance on Eosinophilic cardiomyopathy NHS PRODIGY Guidance FDA on Eosinophilic cardiomyopathy CDC on Eosinophilic cardiomyopathy
Books
Books on Eosinophilic cardiomyopathy
News
Eosinophilic cardiomyopathy in the news Be alerted to news on Eosinophilic cardiomyopathy News trends on Eosinophilic cardiomyopathy
Commentary
Blogs on Eosinophilic cardiomyopathy
Definitions
Definitions of Eosinophilic cardiomyopathy
Patient Resources / Community
Patient resources on Eosinophilic cardiomyopathy Discussion groups on Eosinophilic cardiomyopathy Patient Handouts on Eosinophilic cardiomyopathy Directions to Hospitals Treating Eosinophilic cardiomyopathy Risk calculators and risk factors for Eosinophilic cardiomyopathy
Healthcare Provider Resources
Symptoms of Eosinophilic cardiomyopathy Causes & Risk Factors for Eosinophilic cardiomyopathy Diagnostic studies for Eosinophilic cardiomyopathy Treatment of Eosinophilic cardiomyopathy
Continuing Medical Education (CME)
CME Programs on Eosinophilic cardiomyopathy
International
Eosinophilic cardiomyopathy en Espanol Eosinophilic cardiomyopathy en Francais
Business
Eosinophilic cardiomyopathy in the Marketplace Patents on Eosinophilic cardiomyopathy
Experimental / Informatics
List of terms related to Eosinophilic cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Eosinophillic Cardiomyopathy also known as Loeffler's Syndrome is a type of restrictive cardiomyopathy caused by eosinophillic infiltration of the endomyocardium. It is a feature of Hypereosinophilic Syndrome and occurs in 40-50% of all cases. Eosinophills enter the tissue and undergo degranulation; release cytotoxic proteins; increase production of reactive oxygen species, enzymes, growth factor, and cytokines. This process leads to tissue damage and dysfunction, eventually leading to fibrosis and restrictive cardiomyopathy. There are 3 stages of the Eosinophilic cardiomyopathy:

• Stage 1: Acute necrotic stage
• Stage 2: Mural thrombi/ thrombus formation
• Stage 3: Fibrotic stage

There are many causes of Hyperesosinophilic Syndrome (HES) with Eosinophilic Cardiomyopathy, these can be classified as:

• Reactive
  • Eosinophillic Granulomatosis Polyangitis
  • Parasitic Infection
  • Autoimmune disorder
  • Medication related
• Clonal Myeloid Disorder
• Idiopathic Hypereosinophillic Syndrome

Historical Perspective

• Eosinophillic Cardiomypoathy was first discovered by Wilhem Loeffler, a Swiss Physician, in 1936 during/following [event].

Classification

• Eosinophilic Cardiomyopathy may be classified according to cause into three subtypes/groups:

• Reactive
• Clonal myeloid disorder
• Idiopathic hypereosinophillic syndrome

Pathophysiology

• The pathogenesis of Eosinophilic Cadiomyopathy is characterized by hypereosinophilia , thrombi formation , restrictive cardiomyopathy , and heart failure .
• The FLP1L1-PDGFRA fusion gene has been associated with the development chronic eosinophilic leukemia and hypereosiniophilic syndrome.
• The PDGFRa, PDGFRb, and PDGFR1 genes have been associated with the development of clonal myeloid disorders leading to hypereosiniophilic syndrome.
• On gross pathology, cardiac hypertrophy and fibrosis are characteristic findings of Eosinophilic Cardiomyopathy.
• On microscopic histopathological analysis, hypereosinophilia, myocardial and myofibrillar disarray, and endoperimysial interstitial fibrosis are characteristic findings of Eosinophilic Cardiomyopathy.

Clinical Features

• Dyspnea
• Chest pain
• Cough
• Embolic events
• Fever

Differentiating [disease name] from other Diseases

• Eosinophilic Cardiomyopathy must be differentiated from other diseases that cause Cardiac hypertrophy, cardiac fibrosis, and Heart failure, such as:

• Amyloidosis
• Sarcoidosis
• Hemachromatosis

Epidemiology and Demographics

• The prevalence of Hypereosinophilic Syndrome is approximately 0.036 per 100,000 individuals worldwide.

Age

• Patients of all age groups may develop Eosinophilic Cardiomyopathy.
• Eosinopilic cardiomyopathy is more commonly observed among patients aged 20-50 years old.

Gender

• Men are more commonly affected with eosinophilic cadiomyopathy than Females.
• The Male to Female ratio is approximately 1.47.

Race

• There is no racial predilection for Eosinophilic Cardiomyopathy.

Risk Factors

• Common risk factors in the development of Eosinophilic Cardiomyopathy are HLA Bw44 positivity, splenomegaly, thrombocytopenia, elevated vitamin B12 levels,

dysplastic eosinophils, and abnormal early myeloid precursors.

Natural History, Complications and Prognosis

• Some patients with Eosinophilic Cardiomyopathy may present asymptomatic.
• Early clinical features include dyspnea, fever, and chest pain.
• If left untreated, patients with Eosinophilic Cardiomyopathy may progress to develop heart failure, arrythmias, and sudden cardiac death.
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of Hypereosinophilic syndrome is made when at least one of the following three diagnostic criteria are met:

• an elevated eosinophil count (>1500/mm3) on 2 separate tests (≥1 mo)
• tissue hypereosinophilia based on >20% eosinophils in a bone marrow section
• marked disposition of eosinophilic granule proteins in tissue plus organ damage directly due to hypereosinophilia

Symptoms

• Eosinophilic Cardiomyopathy is may present asymptomatic early in the course.
• Symptoms of Eosinophilc Cardiomypoathy may include the following:

• Fever
• Dyspnea at rest or on exertion
• Chest pain
• Cough
• Rash
• Malaise

Physical Examination

• Patients with Eosinophilic Cardiomyopathy usually appear distressed.
• Physical examination may be remarkable for:

• Fever
• Tachycardia
• Tachypnea
• Arrythmia
• Rash
• Embolic events

Laboratory Findings

• A positive cardiac biopsy is diagnostic of eosinophilic cardiomyopathy.
• An elevated concentration of eosinophils in peripheral blood smear is diagnostic of Hypereosinophilic syndrome.
• Other laboratory findings consistent with the diagnosis of Eosinophilic cardiomyopathy include abnormal bone marrow biopsy, and abnormal troponins.

Imaging Findings

• Cardiac MRI is the imaging modality of choice for Eosinophilic cardiomyopathy.
• On Cardiac MRI, Eosinophilic Cardiomyopathy is characterized by hyper-enhancement and thrombus formation.
• Echocardiography may demonstrate endomyocardial thickening, ventricular thrombus formation, and mitral valve involvment.

Other Diagnostic Studies

• Eosinophilic Cardiomyopathy may also be diagnosed using ECG.
• Findings on ECG include T wave inversion, Left atrial enlargement, Left ventricular hypertrophy, and Right bundle branch block.

Treatment

Medical Therapy

• The treatment of Eosinophilic Cardiomyopathy depends on the underlying cause.
• The mainstay of therapy is supportive care.

• The mainstay of therapy for Eosinophilic Cardiomyopathy with a FIP1L1-PDGFRA mutation is imatinib and steroids.
• Symptomatic management includes diuretics, Beta Blockers, ACE inhibitors, Angiotensin Receptor Blockers, and Digoxin.
• Imatinib acts by inhibition of tyrosine kinase.
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• Valve replacement may be performed for patients with valvular damage in Eosinophilic Cardiomyopathy.
• Cardiac Transplant may be performed for patients with irreversible damage in Eosinophilic Cardiomyopathy.

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].